Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Answer

Staff  |  Issue: January 2010  |  January 1, 2010

Read the Question.

Answer:
99213-25, 96413, 96415×1, J1745x20 Diagnosis 714.0

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Modifier -25 is used to indicate that the patient received a significant, separately identifiable E/M service on the same day as her infliximab infusion. This E/M service is coded this way because:

  • The history is expanded problem-focused;
  • The examination is expanded problem-focused; and
  • The medical decision making is of low complexity.

Infliximab is considered a chemotherapy infusion. The code 96413 is used for the first hour of a chemotherapy infusion and 96415 is used to code each additional hour of a chemotherapy infusion, up to eight hours. Because the patient’s infliximab was infused over two hours and 10 minutes, it is coded 96413 and 96415×1. The time for the infusion starts when the actual medication is started, not when the IV port is inserted. J1745 is the drug code for infliximab 10 mg. Because the patient received 200 mg of infliximab, the correct way to code this is J1745x20 (20 x 10 mg=200 mg).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Share: 

Filed under:Billing/CodingPractice Support Tagged with:BillingCodingE/M serviceInfusionRheumatoid arthritis

Related Articles

    Coding Corner Answer: July Coding Challenge

    July 1, 2013

    Coding for a patient who gets subsequent infusions of infliximab

    Coding Corner Answer: August Coding Challenge

    August 8, 2012

    A 43-year-old female established patient diagnosed with rheumatoid arthritis comes to the office for her first infliximab infusion.

    Coding Corner Answer: March

    March 1, 2015

    Coding for chemotherapy infusion with a drug reaction

    Documenting Infusion Time, Start to Finish

    January 1, 2010

    Has your practice ever experienced the disappointment of being downcoded because of lack of supporting documentation?

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences